Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which completed Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montréal, Canada.

Market Cap	$224.00M	P/E Ratio	N/A
52W High	$2.77	52W Low	$0.63
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	13.1%	52W Position	83.2%
Overall Score	58	Value Score	40
Quality Score	36	Technical Score	100

EPS Current Est	$-0.73	EPS Next Est	$-0.98
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MIST	$2.41	-18.31%	28.04M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MIST	$2.41	-18.3%	28.04M
3
4
5
6

MIST

MIST

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Milestone Pharmaceuticals Inc. Data in Excel

Get Milestone Pharmaceuticals Inc. Data in Excel